# ATXN3 WILDTYPE Research Report **Protein:** ATXN3 WILDTYPE **Variant:** Q27 **UniProt ID:** P54252 **Disease Association:** Spinocerebellar ataxia type 3 (Machado-Joseph) **Report Generated:** 2026-07-29 20:22 UTC **AlphaFold Confidence (pLDDT):** 72.1% **Structure Folded:** 2026-07-27 --- ## Structure Summary ATXN3 is a protein whose genetic mutation causes Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, a progressive neurological disorder affecting movement and coordination. This analysis examined the structure of wildtype (normal) ATXN3 with 27 glutamine residues (Q27), revealing a moderately confident structural prediction (average confidence 72.1 out of 100). Understanding the normal protein structure provides a crucial baseline for comparing how disease-causing mutations with expanded glutamine repeats alter ATXN3's shape and function. --- Spinocerebellar ataxia type 3 (SCA3) is caused by CAG repeat expansions in the ATXN3 gene, which encode abnormally long polyglutamine (polyQ) tracts in the ataxin-3 protein [1]. Normal ATXN3 contains approximately 12-44 glutamine residues, while disease-causing mutations typically contain 55-87 repeats [2]. This structural analysis examined wildtype ATXN3 with 27 glutamines (Q27), representing a normal, non-pathogenic form of the protein. The structure was predicted using AlphaFold2/ColabFold computational methods, achieving an average confidence score (pLDDT) of 72.1, indicating moderate overall reliability with likely regions of both well-defined and uncertain structure. ATXN3 functions as a deubiquitinating enzyme that removes ubiquitin molecules from proteins, playing important roles in protein quality control and cellular stress responses. Recent research has revealed that mutant ataxin-3 with expanded polyglutamine tracts undergoes liquid-liquid phase separation (LLPS), forming droplets that can transition into solid aggregates and nuclear inclusions characteristic of SCA3 pathology [3]. Single-cell RNA sequencing studies have identified impaired heat stress response pathways in SCA3, specifically involving CHIP-mediated protein quality control mechanisms [1]. Understanding the normal Q27 structure provides a critical reference point for identifying how expanded polyglutamine repeats alter protein folding, stability, and interaction properties. The moderate confidence level (pLDDT 72.1) suggests this structure contains both well-resolved regions, likely including the catalytic domain and ubiquitin-interacting motifs (UIMs), and poorly resolved flexible regions. Regions with pLDDT below 70 should be interpreted with caution, as they may represent intrinsically disordered segments or areas where computational prediction is less reliable. ATXN3 contains multiple functional domains including UIMs that recognize ubiquitin chains, and the polyglutamine tract itself may contribute to structural flexibility in the normal protein [3]. Clinically, SCA3 is one of the most common dominantly inherited ataxias, presenting with progressive gait instability, cerebellar ataxia, and spasticity [2]. Disease onset and progression correlate inversely with CAG repeat length, though genetic modifiers like ATXN2 intermediate repeats also influence pathogenesis [4]. Recent longitudinal studies tracking biological markers in SCA3 patients have identified predictors of clinical progression, informing our understanding of disease mechanisms [5]. Genome editing approaches targeting the expanded ATXN3 gene have shown promise in cellular models, improving cellular structures like the Golgi apparatus that are disrupted by mutant ataxin-3 [6]. The Q27 wildtype structure analyzed here represents the normal baseline against which these pathogenic changes can be understood, though the moderate confidence score indicates that experimental validation would strengthen structural interpretations, particularly in lower-confidence regions. ## Works Cited [1] Tang et al. (2026). Single-Cell RNA Sequencing Reveals Impaired CHIP-Mediated Heat Stress Response in SCA3 Pathogenesis. Molecular neurobiology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41701293/) [2] Wang et al. (2025). Familial spinocerebellar ataxia type 3: A case report of multi-generational presentation. Medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40797466/) [3] Prasad et al. (2025). Rad23B Delays Ataxin-3 Liquid-to-solid Phase Transition Through Heterotypic Buffering. Journal of molecular biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684934/) [4] Lauerer et al. (2025). Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis. Acta neuropathologica communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684213/) [5] Berger et al. (2025). Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort. The Lancet regional health. Europe. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40678042/) [6] Wang et al. (2025). Genome editing in spinocerebellar ataxia type 3 cells improves Golgi apparatus structure. Scientific reports. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40204795/) ## Similar Research **Integrative genetic analysis illuminates ALS heritability and identifies risk genes.** Megat et al. (2023) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/36670122/) **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Frontotemporal dementia. How to deal with its diagnostic complexity?** Antonioni et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39911129/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **MATR3 pathogenic variants differentially impair its cryptic splicing repression function.** Khan et al. (2024) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/38320753/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Machado-Joseph disease | 0.568 | literature, animal_model, genetic_association, genetic_literature | | Spinocerebellar ataxia type 3 | 0.493 | literature, animal_model, genetic_association | | Abnormality of the skeletal system | 0.400 | genetic_association | | Machado-Joseph disease type 1 | 0.377 | animal_model, genetic_association | | Machado-Joseph disease type 2 | 0.377 | animal_model, genetic_association | | Machado-Joseph disease type 3 | 0.370 | genetic_association | | Parkinson disease | 0.204 | literature, animal_model, genetic_association | | late-onset Parkinson disease | 0.196 | animal_model, genetic_association | | Hereditary late-onset Parkinson disease | 0.193 | animal_model, genetic_association | | hereditary disease | 0.193 | literature, genetic_association | *...and 865 more associations* --- ## AI Research Brief # Research Brief: ATXN3 Wildtype Q27 Variant ## Pathogenic Mechanisms ATXN3 encodes ataxin-3, a cysteine-type deubiquitinase that plays critical roles in protein quality control and cellular stress responses. The Q27 wildtype variant contains 27 glutamine residues, representing a normal CAG repeat length below the pathogenic threshold of 52-86 repeats that characterize Machado-Joseph disease (SCA3). Recent literature demonstrates that wildtype ATXN3 exhibits distinct phase separation properties compared to pathogenic expanded variants, suggesting that polyglutamine tract length fundamentally alters protein biophysical behavior. The protein's deubiquitinase activity and ATPase binding capacity are essential for normal cellular functions including actin cytoskeleton organization, response to amino acid starvation, and heat stress adaptation. Key protein-protein interactions with VCP, BECN1, and caspases (CASP1, CASP3) implicate ATXN3 in autophagy and apoptotic pathways, which become dysregulated when polyglutamine expansion occurs. Understanding wildtype Q27 function establishes the baseline against which pathogenic mechanisms can be compared. ## Clinical Significance The Q27 wildtype variant represents the normal, non-pathogenic form of ATXN3 and serves as a critical reference point for understanding SCA3 pathogenesis. Collection of baseline data for this normal-range variant is essential for defining the threshold where polyglutamine expansion triggers neurodegeneration. Unlike pathogenic variants (≥52 repeats) that cause progressive cerebellar ataxia, ophthalmoplegia, and pyramidal signs, the Q27 variant maintains normal protein structure and function. This baseline characterization is clinically valuable for developing therapeutic strategies that aim to selectively reduce mutant ATXN3 while preserving wildtype protein function, as complete loss of ATXN3 may have deleterious consequences given its essential roles in protein quality control and stress response pathways. ## Therapeutic Landscape Structural analysis reveals aggregation hotspots at residues 148-152 (aggregation score: 0.56), identifying a potential target region even in wildtype ATXN3. The candidate peptide CP-ATXN3-001 has been computationally designed to target this 148-152 region, which may represent a conserved aggregation-prone segment that becomes pathologically relevant when polyglutamine tracts expand. This therapeutic approach rationally targets a region distinct from the polyglutamine tract itself, potentially offering opportunities to modulate protein aggregation without directly addressing repeat length. Understanding whether this region exhibits differential aggregation propensity between Q27 and expanded variants could inform peptide-based therapeutic strategies that selectively interfere with pathogenic aggregation while sparing normal protein function. ## Research Directions Critical knowledge gaps include determining how the Q27 wildtype variant's phase separation properties differ quantitatively from pathogenic variants, and whether aggregation hotspot regions (148-152) show enhanced aggregation propensity in expanded variants. Future research should establish comprehensive structural and functional baselines for Q27, including post-translational modifications and interactome mapping under various cellular stress conditions. Gene editing approaches that preserve wildtype alleles while targeting expanded repeats warrant investigation. Additionally, validating CP-ATXN3-001's specificity and efficacy in preventing pathogenic aggregation without disrupting normal ATXN3 function represents an actionable therapeutic direction. Understanding genetic modifiers that influence the pathogenic threshold could reveal why some individuals with intermediate repeats remain asymptomatic. --- ## Agent Findings ### Literature (1) - **2026-07-27:** These papers provide critical insights into SCA3 pathogenesis mechanisms involving wild-type and mutant ATXN3, including phase separation properties of the Q27 wild-type variant, cellular stress responses, protein aggregation dynamics, and genetic modifiers. The findings are directly relevant for understanding how wild-type ATXN3 Q27 differs from pathogenic expanded polyglutamine variants, establishing biomarkers for disease progression, and identifying potential therapeutic targets through gene editing and pathway modulation. ### Clinical (1) - **2026-07-27:** The Q27 wildtype ATXN3 variant represents a normal CAG repeat length (27 glutamines) below the pathogenic threshold of 52-86 repeats. First baseline data collection for this normal-range variant is clinically significant because it establishes reference parameters for comparing against pathogenic expansions, helping to define the normal protein structure and function that becomes disrupted in Machado-Joseph disease. This baseline data is essential for understanding the molecular mechanisms by which expanded polyglutamine tracts cause neurodegeneration and may inform therapeutic strategies aimed at reducing mutant ATXN3 protein while preserving normal protein function. ### Structural (1) - **2026-07-28:** AlphaFold structure update: Baseline check: 5 structure(s) found ### Synthesis (1) - **2026-07-28:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The ATXN3 wildtype Q27 variant represents a normal polyglutamine repeat length that serves as a crit... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)